Mirum Pharmaceuticals Inc To Discuss FDA Approves LIVMARLI Call Transcript
Welcome to Mirum Pharmaceuticals conference call to discuss the FDA approval of LIVMARLI. (Operator Instructions)
I will now turn the call over to Mirum's CFO, Ian Clements. You may proceed.
Thank you, operator. Good afternoon, everybody. Thank you for joining us to discuss the exciting news we announced earlier today regarding the FDA approval of LIVMARLI or maralixibat for the treatment of cholestatic pruritus in patients with Alagille syndrome. With me on the call is our President and CEO, Chris Peetz; Chief Operating Officer, Peter Radovich; and Chief Strategic Officer, Pam Vig.
Before we begin, I'd like to remind you that during the course of this conference call, we will be making certain forward-looking statements about Mirum and management's current expectations, including statements regarding Mirum's business plans, development programs, strategies, prospects, commercialization and market opportunities, financial forecasts and guidance, anticipated FDA interactions or announcements and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |